AMES, IA--(Marketwired - Aug 7, 2013) - NewLink Genetics Corporation (NASDAQ: NLNK) today reported consolidated financial results for the second quarter of 2013 and reviewed progress in its development programs.

NewLink reported a net loss for the second quarter 2013 of $7.1 million or $.28 per common share (based on 25.6 million weighted average shares outstanding), compared with $6.3 million, or $.31 per common share, for the second quarter 2012 (based on 20.7 million weighted average shares outstanding).

Total grant revenues for the second quarter 2013 were $232,000 compared with $590,000 for the second quarter 2012. Research and development expense for the second quarter 2013 was $5.0 million compared with $4.7 million for the second quarter 2012. General and administrative expense for the second quarter 2013 was $2.3 million compared with $2.2 million for the second quarter 2012.

NewLink ended the second quarter with cash, cash equivalents and certificates of deposit totaling $59.0 million and continues to expect to end the year with about $40 million in cash, cash equivalents and marketable securities.

"We presented an array of compelling clinical and preclinical data across our pipeline of novel immunotherapies at some of the most prominent cancer meetings this quarter. This included clinical data on NewLink's HyperAcute immunotherapies and our novel IDO pathway inhibitor, indoximod. In addition, preclinical data on NLG919, our second IDO pathway inhibitor were presented at ACCR," commented Dr. Charles Link, Chairman and Chief Executive Officer of NewLink. "Patient accrual remains on track for the many clinical trials currently underway, including enrollment in the Phase 3 IMPRESS trial for surgically resected pancreatic cancer. In addition, we have made significant progress in the Phase 2b/3 trial for patients with previously treated non-small-cell lung cancer and in Phase 2 trials in other settings. We look forward to reporting further progress with these programs in the months to come."

Second Quarter and Recent Accomplishments

Pipeline:

Corporate:

About NewLink Genetics Corporation

NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit http://www.linkp.com. Patient information is available at http://www.pancreaticcancer-clinicaltrials.com.

Read the original here:
NewLink Genetics Corporation Reports Second Quarter 2013 Financial Results

Comments are closed.